HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

24 MONTH VULVAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 24 month CRF: please complete any additional treatment details that were not captured at 6 or 12 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- · Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID	/[/						
Participant's date of birth	d	d	m	m	У	У	У	У	

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Participant's Study ID	

Clinical diagnosis of depression	
Psychiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

Participant's Study ID		
Is the participant pre or pos	st menopause? (p	lease tick one box)
Pre menopause		

Post menopause

Unknown

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Neo-adjuvant chemotherapy	Drug(s), please give details		/ / 20	// 20	
	Neo-adjuvant chemotherapy num	ber of cycle	s, please enter on line		
Neo-adjuvant radiotherapy	External radiotherapy		// 20	// 20	
	Number of radiotherapy fractions	, please ente	er on line		_
	Dose for each radiotherapy fraction	on please en	ter on line		

Participant's Study ID	7	7		
rarticipant s stady 15	/_//	/		

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Surgery	Sentinel lymph node biopsy		// 20		
	Groin/inguinal lymph node dissection		// 20		
	Radical wide local excision / Wide local excision		// 20		
	Radical partial vulvectomy / Partial vulvectomy		// 20		
	Radical vulvectomy		// 20		
	Pelvic exenteration		// 20		
	Vulval reconstruction		// 20		
	Plastics surgery (please describe)		// 20		
	Other surgery (please describe)				

	 	 _	 	
Participant's Study ID	/	/		

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat - ment (if fin- ished) (dd/mm/yyyy)	If course of treat - ment was not completed as planned, please give a reason why	
Adjuvant Chemo- therapy or	Cisplatin		/ / 20	// 20		
Chemoradiation	Fluorouracil (5-FU)		// 20	// 20		
(please tick all that apply and give details for any radiotherapy	Mitomycin		// 20	// 20		
below)	Carboplatin		// 20	// 20		
	Paclitaxel/Taxol		/ / 20	// 20		
	Capcitabine		/ / 20	/ / 20		
	Other (please describe below):		/ / 20	// 20		
	Chemotherapy number of cyc	l cles, please e	l enter on line			
Radiotherapy	External radiotherapy		// 20	// 20		
	Number of radiotherapy fra	ictions, pleas	se enter on line			
	Dose for each radiotherapy	fraction plea	se enter on line			
	Brachytherapy		// 20	_ / / 20		
	Number of radiotherapy fractions, please enter on line					
	Dose for each radiotherapy	fraction plea	ase enter on line			
Other	Other treatment		/ / 20	/ / 20		
	e.g. clinical trial treatment (please describe)					
	W 3300					

Participant's Study ID / /						
Were any of the treatments detailed given with palliative intent?						
(please tick one box) Yes No Unknown						
If yes, please indicate which treatments?						
Has the participant had a local recurrence of their Vulval cancer? (please tick one box) Yes No Unknown						
If the participant has had a local recurrence, on what date was the recurrence						
diagnosed?						
Since the participant's diagnosis of their Vulval cancer, has there been any evidence of distant metastatic disease? (please tick one box) Yes No Unknown						
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:						
d d m m y y y y						
Please provide details of the site(s) of distant metastatic disease:						
Is the participant taking part in a clinical trial? (please tick one box)						
Yes Unknown						
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in Name of clinical trial HORIZONS; 24 month Case Report Form; Vulval. Version 1.0, 03/09/2019, IRAS Project ID: 202342, REC reference number 16/NW/0425						

Participant's Study ID / /				
Since the participant's diagnosis of Vulval cancer, have they been diagnosed with another new primary cancer? (please tick one box)				
Yes No	Unknown			
If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below				
Type of cancer				
Date of diagnosis	// 20			
Treatment received				
Date treatment ended (if finished)	// 20			
What type of follow-up care is the participant receiving? (please tick ONE box)				
Routine/regular hospital clinic based follow-up (medical or nurse led,				
face-to-face or by telephone)				
Primary care based follow-up				
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)				
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?				

Participant's Study ID / /	
-	cipant been referred to any of the following services and/or had a s Assessment? (please tick all that apply)
Participant ha	as been referred to palliative care services
If available, p	lease give reason for referral (e.g. end of life care, symptom management)
Participant h	as been referred to psychological services
If ticked, please	provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant h	as been referred to community services
Participant ha	as been referred for treatment related problems (e.g. urology,
gastroentero	logy) If ticked, please provide more details below:
Participant ha	as had an HNA (holistic needs assessment)
Participant's o	ant has died please give the date and cause of death: date of death dd / mm / y y y y icipant's death
1) a)	
1) b)	
1) c)	
2)	
Cause of deat	h not known
Please add y	our name and signature and the date that you completed this CRF
Name	Signature
Date CRF co	mpleted dd / m m / y y y y